FDA Approves Drug to Treat Lesions Caused by Herpes Simplex Virus
The FDA approved pritelivir tablets for specified mucocutaneous HSV lesions in immunocompromised adults whose infections resist standard antivirals.
TL;DR
- The FDA approved Hovilpri (pritelivir) for mucocutaneous HSV lesions in immunocompromised adults who did not respond to specified antivirals.
- The approved use covers lesions caused by HSV-1 or HSV-2 that are refractory to acyclovir, valacyclovir, or famciclovir.
- The approval does not cover all people with HSV or establish use for other populations.
The U.S. Food and Drug Administration approved Hovilpri, the brand name for pritelivir tablets, for immunocompromised adults with mucocutaneous lesions caused by herpes simplex virus who have not responded to other treatments. The FDA notice identifies acyclovir, valacyclovir, and famciclovir as the prior therapies. [1] [2]
Asahi Kasei Therapeutics’ announcement describes the approved indication as lesions refractory, with or without documented resistance, to those standard antiviral treatments. The company identifies pritelivir as a helicase-primase inhibitor. [1] [2]
The indication is limited to the specified patient group and disease presentation. The approval notice does not say that the drug cures HSV, which can remain latent, and it should not be generalized to immunocompetent people or other uses. [1] [2]
FDA approval establishes authorization for this labeled use; questions about real-world uptake, comparative outcomes, and post-market safety will require evidence after launch. This summary reports the regulatory action and is not treatment guidance. [1] [2]
Why it matters
The decision adds an FDA-authorized option for a narrowly defined group with refractory HSV lesions, while the label’s population limits remain central to interpreting the approval.
Editor's note
The FDA notice and manufacturer release agree on the approved indication. No dosing or treatment advice is included.